Ana-Isabel Teruel

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · The Lancet Oncology · 2010 · 459 citations · Full text

Medicine, Hematology, Pharmacology +17

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

Juan José Lahuerta, Bruno Paiva, María‐Belén Vídriales et al. · Journal of Clinical Oncology · 2017 · 318 citations · Full text

Medicine, Hematology, Oncology +17

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

Bruno Paiva, Joaquín Martínez‐López, María‐Belén Vídriales et al. · Journal of Clinical Oncology · 2011 · 233 citations · Full text

Medicine, Hematology, Oncology +13

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Bruno Paiva, María‐Teresa Cedena, Noemí Puig et al. · Blood · 2016 · 150 citations · Full text

Medicine, Hematology, Oncology +17

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · Blood · 2012 · 144 citations · Full text

Medicine, Hematology, Oncology +15